indication

Schizophrenia

SCHIZOPHRENIA
as of 2026-07-01
Open landscapeMonitor thisAsk about this
at a glance
US prevalence envelope 655,000–3,144,000 (range by case definition)
2924 trials in this indication
Synthesized from structured facts only — each point cited above.

Coding & identity

Trials
2,924

Market size

prevalence as a range, not a number
US prevalence envelope (implied people)
655K – 3.1M
spans ~4.8× by case definition — each source below
US prevalence range (household/clinical/records)0.25–0.64%
under-counts institutionalized/incarcerated/homeless; schizophrenia often combined with other psychotic disorders
international non-institutionalized prevalence0.33–0.75%
international, non-institutionalized
lifetime prevalence base case0.72–1.19%
lifetime, includes schizoaffective (F25)
schizophrenia-spectrum, adults 18-651.2%
spectrum (broader than schizophrenia alone)
commonly-cited US figure0.9%
round-number industry convention

Standard of care

treatment guidelines
CG178
National Institute for Health and Care Excellence (NICE) · UK · reviewed 2025-07-29
  • first-episode treatmentoral antipsychotic + psychological intervention (family + CBT) offered together
  • antipsychotic choiceno single antipsychotic preferred; choice is shared decision driven by side-effect profile across 5 dimensions
  • side-effect dimensionsmetabolic (weight/diabetes), extrapyramidal (akathisia/dyskinesia/dystonia), cardiovascular (QT), hormonal (prolactin), subjective experience
  • at-risk / preventiondo NOT offer antipsychotics to prevent psychosis or to at-risk individuals
  • therapeutic trialtreat as explicit individual trial; start low end of licensed range, titrate up; 4-6 week trial at optimal dose
APA 2020
American Psychiatric Association (APA) · US
  • pharmacotherapy[1A]treat with an antipsychotic and monitor effectiveness + side effects
  • continuation[2B]continue the SAME antipsychotic if symptoms improved
  • agent selection[n/a]NO preference between first- and second-generation; select on side-effect profile, formulation availability, drug-drug interactions, metabolism
  • treatment-resistant[1B]clozapine for treatment-resistant schizophrenia, or substantial suicide/aggression risk
  • long-acting injectable[2B]LAI if patient prefers, or history of poor/uncertain adherence

Facts & assertions

0 sourced
No assertions recorded for this entity.